In last trading session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) saw 0.56 million shares changing hands with its beta currently measuring 2.79. Company’s recent per share price level of $4.64 trading at -$0.03 or -0.64% at ring of the bell on the day assigns it a market valuation of $214.49M. That closing price of FDMT’s stock is at a discount of -681.25% from its 52-week high price of $36.25 and is indicating a premium of 4.96% from its 52-week low price of $4.41.

For 4D Molecular Therapeutics Inc (FDMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.84 in the current quarter.

4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information

Upright in the red during last session for losing -0.64%, in the last five days FDMT remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $4.64 price level, adding 14.39% to its value on the day. 4D Molecular Therapeutics Inc’s shares saw a change of -16.70% in year-to-date performance and have moved -1.69% in past 5-day. 4D Molecular Therapeutics Inc (NASDAQ:FDMT) showed a performance of 0.65% in past 30-days.

Wall Street analysts have assigned a consensus price target of 37.5 to the stock, which implies a rise of 87.63% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 40. It follows that stock’s current price would drop -29.31% in reaching the projected high whereas dropping to the targeted low would mean a loss of -29.31% for stock’s current value.

4D Molecular Therapeutics Inc (FDMT) estimates and forecasts

This year revenue growth is estimated to fall -93.32% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.28M for the same. And 3 analysts are in estimates of company making revenue of 176k in the next quarter. Company posted -19k and 28k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.35% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -12.47% while estimates for its earnings growth in next 5 years are of -15.10%.

4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders

BLACKROCK INC. is the top institutional holder at FDMT for having 4.9 million shares of worth $102.79 million. And as of 2024-06-30, it was holding 9.9385 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 5.1 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2221 of outstanding shares, having a total worth of $107.01 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.54 shares of worth $7.13 million or 3.33% of the total outstanding shares. The later fund manager was in possession of 1.42 shares on Nov 30, 2024 , making its stake of worth around $6.59 million in the company or a holder of 3.07% of company’s stock.